Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Brian Benson

Podiatrist, Foot & Ankle Surgery Leesville, LA Doctor of Podiatric Medicine

NPI 1104350883 CMS profile 7528095

1108 Port Arthur Ter, Leesville, LA 71446

Open in the dashboard

General payments

$278,387

301 records reported · program years 2020–2025

Research payments

$18,225

Paid to them · 2 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,087 paid to institutions, not to them · program year 2024

Through program year 2025, Brian Benson of Leesville, LA is reported in the CMS Open Payments database as having received $278,387 across 301 general payments and $18,225 in research payments paid to them. Separately, studies naming them as principal investigator received $9,087 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $96,957 71
2024 General $58,956 54
2023 General $69,113 74
2023 Research $18,225 2
2022 General $40,586 40
2021 General $12,278 60
2020 General $498 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Benson
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Brian Benson were reported at $96,957. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Brian Benson Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $498 $191 $62–$691 $114
2021 $12,278 $329 $104–$1,341 $132
2022 $40,586 $419 $125–$1,611 $149
2023 $69,113 $377 $128–$1,164 $160
2024 $58,956 $394 $134–$1,168 $164
2025 $96,957 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Bone Support Inc. $99,481 61 payments
  2. MedShape, Inc. $47,995 65 payments
  3. Fusion Orthopedics USA, LLC $37,638 21 payments
  4. New Standard Device, LLC dba Metalogix $26,936 3 payments
  5. Linvatec Corporation $21,950 26 payments
  6. Nvision Biomedical Technologies, Inc. $9,970 8 payments
  7. Acera Surgical, Inc. $6,203 12 payments
  8. F&A Foundation, LLC $4,769 1 payment
  9. Alafair Biosciences,Inc. $4,702 3 payments
  10. Trilliant Surgical LLC. $4,057 16 payments
  11. Other $14,686 85 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $220,726 101 payments
  2. Travel and Lodging $39,843 85 payments
  3. Food and Beverage $6,879 106 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,208 2 payments
  5. Education $3,017 4 payments
  6. Debt forgiveness $1,490 1 payment
  7. Royalty or License $1,226 2 payments
Products named General payments · program years 2020–2025
  1. CERAMENTBONE VOID FILLER $99,481 61 payments
  2. CERAMENT G $91,981 58 payments
  3. DynaNail Helix, Washer, 15 mm $37,139 50 payments
  4. DynaClip Bone Fixation System, Quattro, 22mm x 20mm x 20mm $23,139 29 payments
  5. BIOBRACE 23MM $17,757 22 payments
  6. DynaNail $15,384 26 payments
  7. HERCULES SUTURE ANCHOR SYSTEM $12,544 8 payments
  8. Foot/ankle products $5,720 7 payments
  9. VersaWrap $4,702 3 payments
  10. Foot and Ankle $4,250 1 payment
  11. Other $22,836 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Acera Surgical, Inc. $18,225 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

214

Median for Podiatry: 160

Drug cost

$2,064

Median for Podiatry: $2,368

Branded share of claims

16.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 35 $665
Ciclopirox Generic 16 $305
Terbinafine Hcl Generic 31 $235
Clotrimazole Generic 25 $219
Gabapentin Generic 17 $208
Doxycycline Hyclate Generic 16 $181
Meloxicam Generic 39 $117
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $76
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 21 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$2,155,607

Of which drugs: $2,024,278

Medicare patients

196

Average age 75

Services billed

3,597

102 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Arthritis 61%
Chronic kidney disease 44%
Ischemic heart disease 43%
Heart failure 35%
COPD 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Barrera sl or barrera dl, per square centimeter Q4281 Office 13 1,764 $1,870,813

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record